RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer - Summary - MDSpire
From the Journals
Clinical Guidelines

RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer

The treatment landscape for advanced pancreatic cancer is shifting. The common RAS mutation is now targetable and the race for the most effective inhibitor is heating up.  

  • By

  • Caroline Helwick

  • May 8, 2026

  • 13 min

Share

Recent advancements in the treatment of advanced pancreatic cancer have emerged, particularly with the development of daraxonrasib, a potent inhibitor targeting RAS mutations commonly present in pancreatic ductal adenocarcinoma. In a pivotal phase III trial, daraxonrasib demonstrated superior overall survival rates compared to conventional chemotherapy, achieving a median survival of 13.2 months. The drug has been granted Breakthrough Therapy and Orphan Drug designations by the FDA, indicating a significant shift in treatment paradigms for managing this challenging disease.

Original Source(s)

RAS Inhibitor Daraxonrasib in Metastatic Pancreatic Cancer

  • by Caroline Helwick

  • May 8, 2026

Related Content

Acupuncture for Nocturia in Survivors of Prostate Cancer

Guest Editor’s Note: Nocturia, waking up from sleep more than once to urinate, is prevalent in survivors of prostate cancer and is associated with a diminished quality of life and a higher mortality t...

Gerald Hsu, MD, PhD, Named Editor-in-Chief of the ASCO Educational Book

ASCO is pleased to announce the appointment of Gerald Hsu, MD, PhD, as the new Editor-in-Chief of the ASCO Educational Book.    

  • by ASCO

  • May 8, 2026

  • 2 min
National Academy of Medicine Recognizes 100 Newly Elected Members

Election to the National Academy of Medicine recognizes individuals who have demonstrated outstanding professional achievement and commitment to service.